- Search CSN:
- Members: Login to search all areas
- Not a member? Click here to search public areas
![]() |
Apr 28, 2012 - 10:28 pm
This applies specifically to Peripheral T-Cell Lymphomas. At treatment Monday, I was advised by my clinical trial/study nurse that a couple of new combinations are being worked on by Fred Hutchinson: Specifically, I-CEOP, which will combine Istodax (Romidepsin) with Etoposide, vincristine, prednisone, and cycolophosphamide, while eliminating doxorubicin and its well-known toxicities. It has the potential to be an alternative to EPOCH for some patients. Secondly, Istodax combined with Folotyn (Pralatrexate). Of course, trials will determine their ultimate efficacy. As I am here to attest, Istodax has been amazingly successful in defeating and apparently suppressing Peripheral T-Cell Lymphoma (NOS) for three years now. If successful when used in combination with both standard and newly introduced chemo agents, I think that hope continues to increase for our tiny (but growing) bunch of T-cellers. The potential here is for the development and introduction of a standard therapy for PTCL, where none exists now. This would be great news. Must here add that my scans are still NED. Thank you, Lord! |
Joined: Jul 2010
Sounds great!
I don't have T-cell, but hearing this makes me very happy for those that do. I'm so glad your scans are still coming back NED...doesn't get better than that. Thanks for sharing. I live 1 1/2 hours away from Fred Hutchison in Yakima Washington. It's a good feeling living so close to one of the best cancer research centers in the country. Best wishes...Sue
(Follicular NHL-grade2-stage3-typeA-diagnosed 6/10) age 61.